AceLink Therapeutics is Drug Discovery in United States that focus on kidney disease business. Founded in 2019. They cover business area such as operator, drug, genetically associate human disease, novel therapeutic, genetically associate kidney disorder, autosomal dominant polycystic kidney disease, ADPKD, autosomal recessive polycystic kidney disease, ARPKD, Fabry disease, medical practitioner, safe and effective medicine, human genetic disease.
2019
( 5 years old in 2024 )
Kidney Disease
-
39600 Eureka Drive
Suite 151
Newark, CA 94560
United States
Private
operatordruggenetically associate human diseasenovel therapeuticgenetically associate kidney disorderautosomal dominant polycystic kidney diseaseADPKDautosomal recessive polycystic kidney diseaseARPKDFabry diseasemedical practitionersafe and effective medicinehuman genetic disease
* We use standard office opening hours in near AceLink Therapeutics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
AceLink Therapeutics is Drug Discovery business from United States that founded in 2019 (5 years old in 2024), AceLink Therapeutics business is focusing on Kidney Disease.
AceLink Therapeutics headquarter office and corporate office address is located in 39600 Eureka Drive Suite 151 Newark, CA 94560 United States.
AceLink Therapeutics was founded in United States.
In 2024, AceLink Therapeutics is currently focus on kidney disease sector.
Above is snippet of Google Trends for "kidney disease" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with AceLink Therapeutics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
